A breakthrough broadly neutralizing influenza antibody, developed under the umbrella of the Shanghai Institute of Infectious Disease and Biosecurity (SIIDB), has reached a major milestone: it has formally entered industrial application, institute officials announced in a recent press statement.
Named SII-007, the antibody was incubated at SIIDB and spearheaded by a research team led by Ying Tianlei, a part-time principal investigator at the institute. The entire research and early commercialization process was backed by 21 million yuan ($3.1 million) in funding, a structure that combines an upfront patent transfer fee with post-commercialization revenue sharing. Per Ying’s update, the formal patent transfer for the technology was finalized in February 2026, with regulatory approval from China’s National Medical Products Administration expected by the end of the year, clearing the way for the candidate to enter human clinical trials.
SII-007 was engineered to solve a longstanding challenge in influenza prevention and control: the rapid mutation rate of influenza viruses that often renders traditional vaccines and antibodies ineffective. Unlike conventional antibody development frameworks, this candidate leverages a combined R&D system that integrates artificial intelligence and synthetic immunology, breaking through the key technical limitation of limited broad-spectrum activity that plagues most existing influenza antibodies. As a result, the molecule can effectively target and neutralize multiple currently circulating epidemic influenza strains.
As a passive immunotherapy, SII-007 delivers immediate protective effects upon administration, eliminating the two-week immune induction period required for traditional inactivated influenza vaccines. Delivered via aerosol inhalation, the antibody also offers greater usability than injectable alternatives and requires far lower effective doses. Its high molecular stability further allows it to provide protection against severe influenza infection, a critical benefit for high-risk groups such as the elderly and immunocompromised populations.
From a commercial and intellectual property perspective, the core patent portfolio for SII-007 has been fully established, with all intellectual property rights independently owned and regulated by Chinese entities. Leveraging SIIDB’s established technology transfer mechanism, the project secured industrial partnership with a fund under Fosun Pharma within just one month of completing its proof of concept, accelerating progress toward full-scale industrialization.
Founded in 2020 as a joint initiative between the Shanghai municipal government and Fudan University, SIIDB has built an end-to-end technology transfer ecosystem focused on translating early-stage infectious disease research into real-world applications. The institute receives dedicated special funding from the Shanghai government for major breakthrough technology projects, and has trained more than 500 master’s and doctoral students in the fields of infectious disease and biosecurity to date.
To support open innovation across the domestic research community, SIIDB provides free open access to five of its core research platforms, including a vaccine innovation platform and a national-level pathogen sample bank. It also partners with two specialized law firms to deliver precise intellectual property management and commercial risk assessment for both in-house and collaborative projects.
By the end of 2025, SIIDB’s cumulative research output includes 906 papers indexed in the Science Citation Index, 38 established pathogen infection models for research use, and 94 filed national and international patent applications. The total cumulative value of technology transfers completed by the institute has exceeded 44.5 million yuan, a track record that reflects the success of its institutional innovation model.
These outcomes are directly tied to SIIDB’s deliberate focus on institutional and procedural innovation, particularly its commitment to open access innovation infrastructure. In December 2024, the institute launched a joint laboratory with Chongqing Zhifei Biological Products Co Ltd, backed by a total investment of 15 million yuan to advance shared research goals. It has also prioritized global collaboration: in 2023, it established a cross-border joint research center for infectious disease control, designed to strengthen global prevention and control systems focused on source detection and border interception of emerging pathogens.
Wu Fan, director of SIIDB and vice-dean of Shanghai Medical College at Fudan University, noted that building a full-lifecycle technology transfer system requires coordinated input from industrial parks, investment institutions, and research bodies. She emphasized that dedicated concept validation centers are a critical missing link to help early-stage biotech startups cross the so-called “valley of death” that often sinks promising innovations before they reach commercialization.
Wu also issued a warning about the risks associated with acquisitions of early-stage domestic biotech innovations by large multinational corporations, noting that such deals can put promising domestic breakthroughs out of reach of local public health systems. For this reason, she argued, proactive protection of domestic intellectual property and support for independent technology transformation are critical policy priorities. She called for accelerated efforts to roll out supporting policies, industry standards, and clinical guidelines to bring new domestic infectious disease products to market, and to integrate more innovative products into China’s national immunization program.
Looking ahead, SIIDB plans to expand the scale of its special R&D funds, launch a dedicated vaccine concept validation center, and establish a new innovation and technology transfer center focused on diagnostic tools for infectious diseases. The institute’s core strategic focus will remain on addressing threats from emerging and re-emerging infectious diseases and drug-resistant pathogens, to strengthen China’s public health preparedness and advance global biosecurity.